Merida Biosciences
Biotechnology company developing Fc-based biotherapeutics that selectively bind and eliminate pathogenic antibodies to treat autoimmune and IgE‑mediated allergic diseases. Uses protein engineering, structural characterization, and targeted Fc receptor engagement to drive selective antibody clearance and antigen‑specific B cell inhibition. Advancing multiple discovery and preclinical programs toward clinical development.
Industries
Nr. of Employees
small (1-50)
Products
Lead Graves’ disease biotherapeutic (TSHR autoantibody-targeting)
Engineered Fc‑based therapeutic designed to selectively bind and eliminate thyroid‑stimulating hormone receptor (TSHR) autoantibodies to restore normal thyroid signaling while sparing endogenous ligand activity.
IgE-targeted biotherapeutic for allergic diseases
Therapeutic antibody engineered to neutralize and eliminate IgE antibodies to treat IgE‑mediated allergic conditions with the aim of addressing high IgE levels with less frequent dosing and reduced toxicity.
PLA2R-targeted program for primary membranous nephropathy
Program aimed at clearing PLA2R autoantibodies implicated in primary membranous nephropathy to prevent kidney damage while avoiding broad immunosuppression.
MER511
A precision biologic designed to selectively eliminate pathogenic autoantibodies and their B-cell sources while preserving normal immune function for the treatment of Graves' disease and thyroid eye disease.
MER769
A therapeutic antibody engineered to specifically neutralize and eliminate IgE antibodies to disrupt the treatment of food allergy and other IgE-mediated allergic diseases.
MER683
A development candidate designed to rapidly clear and eliminate pathogenic autoantibodies targeting the phospholipase A2 receptor (PLA2R) in primary membranous nephropathy.
Lead Graves’ disease biotherapeutic (TSHR autoantibody-targeting)
Engineered Fc‑based therapeutic designed to selectively bind and eliminate thyroid‑stimulating hormone receptor (TSHR) autoantibodies to restore normal thyroid signaling while sparing endogenous ligand activity.
IgE-targeted biotherapeutic for allergic diseases
Therapeutic antibody engineered to neutralize and eliminate IgE antibodies to treat IgE‑mediated allergic conditions with the aim of addressing high IgE levels with less frequent dosing and reduced toxicity.
PLA2R-targeted program for primary membranous nephropathy
Program aimed at clearing PLA2R autoantibodies implicated in primary membranous nephropathy to prevent kidney damage while avoiding broad immunosuppression.
MER511
A precision biologic designed to selectively eliminate pathogenic autoantibodies and their B-cell sources while preserving normal immune function for the treatment of Graves' disease and thyroid eye disease.
MER769
A therapeutic antibody engineered to specifically neutralize and eliminate IgE antibodies to disrupt the treatment of food allergy and other IgE-mediated allergic diseases.
MER683
A development candidate designed to rapidly clear and eliminate pathogenic autoantibodies targeting the phospholipase A2 receptor (PLA2R) in primary membranous nephropathy.
Services
Integrated discovery through IND/clinical‑stage development of Fc‑based therapeutics, including preclinical studies, clinical operations and regulatory support.
Drug substance and drug product process development, stability and manufacturability assessments, and technology transfer to external cGMP manufacturers.
Integrated discovery through IND/clinical‑stage development of Fc‑based therapeutics, including preclinical studies, clinical operations and regulatory support.
Drug substance and drug product process development, stability and manufacturability assessments, and technology transfer to external cGMP manufacturers.
Expertise Areas
- Protein engineering for biologics
- Precision immunology for antibody‑driven diseases
- Biologics CMC and process development
- Formulation and drug product development
Key Technologies
- Fc engineering and Fc receptor engagement
- Computational protein design
- Atomic‑resolution structural characterization
- Polyclonal epitope mapping
News & Updates
Company launch and Series A financing to support development of a platform of precision therapeutics targeting pathogenic antibodies; lead candidate targets Graves’ disease.
Raised $121 million in Series A financing to launch the company and advance precision therapeutics for autoimmune and allergic diseases. Financing co‑led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures; joined by GV and Perceptive Xontogeny Venture Funds.
Company launch and Series A financing to support development of a platform of precision therapeutics targeting pathogenic antibodies; lead candidate targets Graves’ disease.
Raised $121 million in Series A financing to launch the company and advance precision therapeutics for autoimmune and allergic diseases. Financing co‑led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures; joined by GV and Perceptive Xontogeny Venture Funds.